| Revision as of 09:32, 1 November 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'UNII', 'KEGG', 'CAS_number').← Previous edit |
Latest revision as of 01:31, 30 May 2023 edit undoEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers172,831 edits Importing Wikidata short description: "Chemical compound"Tag: Shortdesc helper |
| (22 intermediate revisions by 18 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
| verifiedrevid = 420483362 |
|
| verifiedrevid = 458433927 |
|
| image = Mertansine mab structure.svg |
|
| image = Mertansine mab structure.svg |
|
⚫ |
<!-- Monoclonal antibody data --> |
|
|
|
| ⚫ |
<!--Monoclonal antibody data--> |
|
|
| type = mab |
|
| type = mab |
|
| mab_type = mab |
|
| mab_type = mab |
|
| source = zu |
|
| source = zu |
|
| target = ] |
|
| target = ] |
|
⚫ |
<!-- Clinical data --> |
|
|
|
|
|
| tradename = |
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = |
|
| pregnancy_AU = |
|
| pregnancy_AU = |
|
| pregnancy_US = |
|
| pregnancy_US = |
|
| pregnancy_category = |
|
| pregnancy_category = |
|
| legal_AU = |
|
| legal_AU = |
|
| legal_CA = |
|
| legal_CA = |
|
| legal_UK = |
|
| legal_UK = |
|
| legal_US = |
|
| legal_US = |
|
| legal_status = |
|
⚫ |
| routes_of_administration = |
|
| legal_status = |
|
|
⚫ |
<!-- Pharmacokinetic data --> |
| ⚫ |
| routes_of_administration = |
|
|
|
| bioavailability = |
|
|
|
|
⚫ |
| protein_bound = |
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| metabolism = |
|
⚫ |
| elimination_half-life = |
| ⚫ |
| protein_bound = |
|
|
| metabolism = |
|
| excretion = |
|
⚫ |
<!-- Identifiers --> |
| ⚫ |
| elimination_half-life = |
|
|
| excretion = |
|
|
|
|
| ⚫ |
<!--Identifiers--> |
|
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID = NA |
|
| ChemSpiderID = none |
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number_Ref = {{cascite|changed|CAS}} |
|
| CAS_number = <!-- blanked - oldvalue: 1008106-64-6 --> |
|
| CAS_number = 1008106-64-6 |
|
⚫ |
| UNII_Ref = {{fdacite|changed|FDA}} |
|
|
| UNII = 0IVD6ASY0W |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
|
| PubChem = |
|
| PubChem = |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
| ⚫ |
| UNII_Ref = {{fdacite|changed|FDA}} |
|
|
| UNII = <!-- blanked - oldvalue: 0IVD6ASY0W --> |
|
|
| KEGG_Ref = {{keggcite|changed|kegg}} |
|
| KEGG_Ref = {{keggcite|changed|kegg}} |
|
| KEGG = <!-- blanked - oldvalue: D09927 --> |
|
| KEGG = D09927 |
|
|
<!-- Chemical data --> |
|
| chemical_formula = |
|
| chemical_formula = |
|
|
|
|
| molecular_weight = |
|
| molecular_weight = |
|
}} |
|
}} |
|
|
'''Lorvotuzumab mertansine''' (IMGN901) is an ]. It comprises the CD56-binding antibody, ] (huN901), with a ] cell-killing agent, DM1, attached using a disulfide linker, SPP. (When DM1 is attached to an antibody with the SPP linker, it is ]; when it is attached with the thioether linker, SMCC, it is emtansine.) |
| ⚫ |
'''Lorvotuzumab mertansine''' (IMGN901) is an ] of ] linked to ] intended for ] positive cancers (e.g. small-cell lung cancer, ]).<ref name=Dimond2010>{{cite news |url=http://www.genengnews.com/analysis-and-insight/antibody-drug-conjugates-stage-a-comeback/77899350/ |title=Antibody-Drug Conjugates Stage a Comeback |date=9 Mar 2010 |author=Dimond }}</ref><ref>. News-medical.net. Retrieved on 2010-11-20.</ref> |
|
|
|
{{cn|date=February 2023}} |
|
|
|
|
|
⚫ |
Lorvotuzumab mertansine is an experimental agent created for the treatment of ] positive cancers (e.g. small-cell lung cancer, ]).<ref name=Dimond2010>{{cite news |url=http://www.genengnews.com/analysis-and-insight/antibody-drug-conjugates-stage-a-comeback/77899350/ |title=Antibody-Drug Conjugates Stage a Comeback |date= 9 March 2010 | vauthors = Dimond PF | work = Genetic Engineering & Biotechnology News }}</ref><ref>. News-medical.net. Retrieved on 2010-11-20.</ref> |
| ⚫ |
It has been granted ] status for ].<ref>http://www.news-medical.net/news/20100308/ImmunoGen-receives-FDA-orphan-drug-designation-for-IMGN901-compound-in-treatment-of-MCC.aspx</ref> |
|
|
|
|
|
|
⚫ |
It has been granted ] status for ].<ref>{{cite web | title = ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC | url = http://www.news-medical.net/news/20100308/ImmunoGen-receives-FDA-orphan-drug-designation-for-IMGN901-compound-in-treatment-of-MCC.aspx | date = 8 March 2010 | work = News-Medical.net }}</ref> |
| ⚫ |
It has reported encouraging Phase II results for ].<ref>{{cite web |url=http://lungcancer.nocancersite.com/html/2011/02/1745.html |title=ImmunoGen Announces Encouraging New Clinical Data With The Company’s IMGN901 Compound In The Treatment Of Small-Cell Lung Cancer |year=2009}}</ref> |
|
|
|
|
|
⚫ |
It has reported encouraging Phase II results for ].<ref>{{cite web |url=http://lungcancer.nocancersite.com/html/2011/02/1745.html |title=ImmunoGen Announces Encouraging New Clinical Data With The Company's IMGN901 Compound In The Treatment Of Small-Cell Lung Cancer |year=2009 }}{{dead link|date=January 2018 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> |
|
|
|
|
|
==References== |
|
==References== |
| Line 57: |
Line 57: |
|
|
|
|
|
{{Monoclonals for tumors}} |
|
{{Monoclonals for tumors}} |
|
|
|
|
|
] |
|
] |
|
] |
|
] |
|
] |
| Line 63: |
Line 65: |
|
{{monoclonal-antibody-stub}} |
|
{{monoclonal-antibody-stub}} |
|
{{antineoplastic-drug-stub}} |
|
{{antineoplastic-drug-stub}} |
|
|
|
|
] |
|